These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 29263173)

  • 1. Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled.
    Hemnes AR; Humbert M
    Eur Respir Rev; 2017 Dec; 26(146):. PubMed ID: 29263173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension.
    Thenappan T; Chan SY; Weir EK
    Am J Physiol Heart Circ Physiol; 2018 Nov; 315(5):H1322-H1331. PubMed ID: 30141981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New horizons in pulmonary arterial hypertension therapies.
    Galiè N; Ghofrani AH
    Eur Respir Rev; 2013 Dec; 22(130):503-14. PubMed ID: 24293466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future perspectives in pulmonary arterial hypertension.
    Simonneau G; Hoeper MM; McLaughlin V; Rubin L; Galiè N
    Eur Respir Rev; 2016 Dec; 25(142):381-389. PubMed ID: 27903660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Sex in the Pathophysiology of Pulmonary Hypertension.
    Docherty CK; Harvey KY; Mair KM; Griffin S; Denver N; MacLean MR
    Adv Exp Med Biol; 2018; 1065():511-528. PubMed ID: 30051404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension.
    de Raaf MA; Beekhuijzen M; Guignabert C; Vonk Noordegraaf A; Bogaard HJ
    Reprod Toxicol; 2015 Aug; 56():45-51. PubMed ID: 26111581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Search for Disease-Modifying Therapies in Pulmonary Hypertension.
    Woodcock CC; Chan SY
    J Cardiovasc Pharmacol Ther; 2019 Jul; 24(4):334-354. PubMed ID: 30773044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation in pulmonary artery hypertension.
    Sakuma M; Toyoda S; Inoue T; Node K
    Vascul Pharmacol; 2019; 118-119():106562. PubMed ID: 31112745
    [No Abstract]   [Full Text] [Related]  

  • 9. Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleus.
    Dunmore BJ; Jones RJ; Toshner MR; Upton PD; Morrell NW
    Cardiovasc Res; 2021 Sep; 117(11):2309-2325. PubMed ID: 33399862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selenoprotein P Promotes the Development of Pulmonary Arterial Hypertension: Possible Novel Therapeutic Target.
    Kikuchi N; Satoh K; Kurosawa R; Yaoita N; Elias-Al-Mamun M; Siddique MAH; Omura J; Satoh T; Nogi M; Sunamura S; Miyata S; Saito Y; Hoshikawa Y; Okada Y; Shimokawa H
    Circulation; 2018 Aug; 138(6):600-623. PubMed ID: 29636330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice.
    Chan SY; Rubin LJ
    Eur Respir Rev; 2017 Dec; 26(146):. PubMed ID: 29263174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Vascular Remodeling to Treat Pulmonary Arterial Hypertension.
    Thompson AAR; Lawrie A
    Trends Mol Med; 2017 Jan; 23(1):31-45. PubMed ID: 27989641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Sugen 5416/Hypoxia Mouse Model of Pulmonary Arterial Hypertension.
    Bueno-Beti C; Hadri L; Hajjar RJ; Sassi Y
    Methods Mol Biol; 2018; 1816():243-252. PubMed ID: 29987825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond a single pathway: combination therapy in pulmonary arterial hypertension.
    Sitbon O; Gaine S
    Eur Respir Rev; 2016 Dec; 25(142):408-417. PubMed ID: 27903663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary hypertension-"state of the art" management in 2012.
    Saxena A
    Indian Heart J; 2012; 64(1):60-73. PubMed ID: 22572428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron homeostasis and pulmonary hypertension: iron deficiency leads to pulmonary vascular remodeling in the rat.
    Cotroneo E; Ashek A; Wang L; Wharton J; Dubois O; Bozorgi S; Busbridge M; Alavian KN; Wilkins MR; Zhao L
    Circ Res; 2015 May; 116(10):1680-90. PubMed ID: 25767292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension.
    Lang IM; Gaine SP
    Eur Respir Rev; 2015 Dec; 24(138):630-41. PubMed ID: 26621977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of vascular endothelial growth factor in pulmonary arterial hypertension. The angiogenesis paradox.
    Voelkel NF; Gomez-Arroyo J
    Am J Respir Cell Mol Biol; 2014 Oct; 51(4):474-84. PubMed ID: 24932885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary arterial hypertension: tailoring treatment to risk in the current era.
    Gaine S; McLaughlin V
    Eur Respir Rev; 2017 Dec; 26(146):. PubMed ID: 29263175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidative and nitrosative signalling in pulmonary arterial hypertension - Implications for development of novel therapies.
    Hansen T; Galougahi KK; Celermajer D; Rasko N; Tang O; Bubb KJ; Figtree G
    Pharmacol Ther; 2016 Sep; 165():50-62. PubMed ID: 27216365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.